Studies related to Treatment of COPD and N-Acetylcysteine

New Developments In The Treatment Of COPD: Comparing The Effects Of Inhaled Corticosteroids And N-acetylcysteine

Effect Increase
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 20
Sex Both Genders
Age Range 45-64, 65+
Body Types Average
Notes for this study:
Supplementation of N-acetylcysteine at 600mg once daily for ten weeks in persons with stable COPD has resulted in less Eosinophil cationic protein (ECP; indicative of granulocyte breakdown) and less adhesion factors, which are thought to underlie the mucolytic properties and sputum reduction.

Full details on all 4 studies are available to Examine members — try free for 7 days.

Already a member? Log in now to access.